

Notes to the Consolidated Financial Statements


For the year ended December 31, 2007


(All amounts in millions of Rupees, unless otherwise stated)

1. (a) Background

Wockhardt Limited ('WL' or 'Company') is a subsidiary of Khorakiwala Holdings and Investments Private Limited. The Company has controlling interest, directly or through subsidiaries, in the following entities during the year ended December 31, 2007:

	Name of subsidiaries	Country of Incorporation	Name of Parent	Percentage of ownership
1	Wockhardt Biopharm Limited	India	Wockhardt Limited	100%
	Vinton Healthcare Limited	India	Wockhardt Limited	100%
	Wockhardt Infrastructure Development Limited	India	Wockhardt Limited	100%
4.	Wockhardt UK Holdings Limited (formerly, Wockhardt UK Limited)	England & Wales	Wockhardt Limited	100%
5.	CP Pharmaceuticals Limited	England & Wales	Wockhardt UK Holdings Limited	100%
б.	Wallis Group Limited	England & Wales	Wockhardt UK Holdings Limited	100%
7.	The Wallis Laboratory Limited	England & Wales	Wallis Group Limited	100%
8.	Wallis Licensing Limited	England & Wales	Wallis Group Limited	100%
9.	Wockhardt UK Limited	England & Wales	Wockhardt EU Operations (Swiss) AG	100%
10.	PWH Limited	England & Wales	Pinewood Laboratories Limited	100%
11.	Wockhardt France (Holdings) S.A.S.	France	Wockhardt EU Operations (Swiss) AG	100%
12.	Girex S.A.S.	France	Wockhardt France (Holdings) S.A.S.	100%
	Pharma 2000 5.A.5.	France	Wockhardt France (Holdings) S.A.S.	100%
14.	Niverpharma S.A.S.	France	Wockhardt France (Holdings) S.A.S.	100%
15.	Negma Lerads S.A.S.	France	Wockhardt France (Holdings) S.A.S.	100%
16.	5.E.G.A. 5.A.5.	France	Wockhardt France (Holdings) S.A.S.	100%
17.	DMH S.A.S.	France	Wockhardt France (Holdings) S.A.S.	100%
	Phytex 5.A.5.	France	Wockhardt France (Holdings) 5.A.5.	100%
19.	Scomedia S.A.S.	France	Wockhardt France (Holdings) 5.A.5.	100%
	Mazal Pharmaceutique 5.A.R.L.	France	Girex 5.A.5.	100%
21.	Hariphar S.C.	France	Pharma 2000 S.A.S. Negma Lerads S.A.S.	80% 10%
			DMH S.A.S.	10%
22	Cap Dermatology S.A.R.L.	France	Niverpharma 5.A.5.	100%
	Chams Informatique S.A.R.L.	France	5.E.G.A 5.A.S.	100%
	S.C.I. Salome	France	5.E.G.A 5.A.5.	99%
			DMH S.A.S.	1%
25.	Negma Beneulex 5.A.	Belgium	Wockhardt France (Holdings) S.A.S. Negma Lerads S.A.S.	54% 46%
26.	Wockpharma Ireland Limited	Ireland	Wockhardt EU Operations (Swiss) AG	100%
27.	Pinewood Laboratories Limited	Ireland	Wockpharma Ireland Limited	100%
28.	Nonash Limited	Ireland	Pinewood Laboratories Limited	100%
29.	Wockhardt EU Operations (Swiss) AG	Switzerland	Wockhardt Limited	100%
30.	Esparma AG	Switzerland	Wockhardt EU Operations (Swiss) AG	100%
31.	CP Pharma (Schweiz) AG	Switzerland	CP Pharmaceuticals Limited	100%
32.		Germany	Wockhardt Limited	100%
33.	Wockhardt Europe Limited	British Virgin Islands	Wockhardt Limited	100%
34.	Wockhardt Nigeria Limited	Nigeria	Wockhardt Europe Limited	100%
	Wockhardt Farmaceutica Do	Brazil	Wallis Laboratory Limited	90%
	Brazil Ltda		Wockhardt Europe Limited	10%
36.	Wockhardt USA, Inc.	USA	Wockhardt EU Operations (Swiss) AG	100%
37.	Atlantis USA, Inc.	USA	Wockhardt Limited	100%
38.	Wockhardt Holding Corporation	USA	Wockhardt EU Operations (Swiss) AG	100%
39.	MGP Holding Corporation	USA	Wockhardt Holding Corporation	100%







	Name of subsidiaries	Country of Incorporation	Name of Parent	Percentage of ownership
40.	Morton Grove Pharmaceuticals, Inc.	USA	MGP Holding Corporation	100%
41.	MGP, Inc.	USA	Morton Grove Pharmaceuticals, Inc.	100%
42.	Wockhardt Cyprus Limited	Cyprus	Wockhardt EU Operations (Swiss) AG	100%

The Company together with its subsidiaries Wockhardt Europe Limited ('WEL'), Wockhardt Biopharm Limited ('WBL'), Wockhardt Infrastructure Development Limited ('WIDL'), Consolidated Wockhardt UK Holdings Limited ('WUK'), Esparma GmbH (EG), Vinton Healthcare Limited and Consolidated Wockhardt EU Operations (Swiss) AG ('WS')(collectively, 'the Group') is primarily engaged in the business of manufacture and marketing of pharmaceutical products. The group has twelve manufacturing locations and there are five locations where research and development activities are carried out.

(b) Basis of consolidation

- (a) The consolidated financial statements of the group have been prepared based on a line-by-line consolidation of the financial statements of Wockhardt Limited and its subsidiaries using uniform accounting policies for like transactions and other events in similar circumstances. All material inter-company balances and transactions are eliminated on consolidation.
- (b) Assets and liabilities of subsidiaries are translated into Indian rupees at the rate of exchange prevailing as at the Balance Sheet date. Revenues and expenses are translated into Indian rupees at average of twelve months closing rates and the resulting net translation adjustment aggregating Rs. 341.33 million (USD 8.66 million) [2006 – Rs. 9.07 million (USD 0.2 million)] has been adjusted to Reserves.
 - Name of subsidiaries Country of Incorporation 1. Wockhardt France (Holdings) S.A.S. France 2. Girex 5.A.5. France 3. Pharma 2000 S.A.S. France 4. Niverpharma S.A.S. France 5. Negma Lerads 5.A.S. France 6. S.E.G.A S.A.S. France 7. DMH 5.A.5. France 8. Phytex S.A.S. France 9. Scomedia S.A.S. France 10. Mazal Pharmaceutique S.A.R.L. France 11. Hariphar S.C. France 12. Cap Dermatology S.A.R.L. France 13. Chams Informatique S.A.R.L. France 14. S.C.I. Salome France 15. Negma Beneulex S.A. Belgium 16. Esparma AG Switzerland 17. Atlantis USA, Inc. USA 18. Wockhardt Holding Corporation USA 19. MGP Holding Corporation USA 20. Morton Grove Pharmaceuticals, Inc. USA 21. MGP, Inc. USA
- (c) During the year, WL along with its subsidiaries, have established following wholly owned subsidiaries:

At the reporting date, this has resulted in an increase in net assets by Rs. 7,305.86 million (USD 185.38 million) and change in Profit before tax by Rs. 553.69 million. (USD 14.05 million).

(d) Convenience translation

The accompanying financial statements have been prepared in Indian rupees, the national currency of India. Solely for the convenience of the reader, the financial statements as of and for the year ended December 31, 2007 have been translated into United States dollars at the closing rate as at December 31, 2007 [USD 1 = Rs. 39.41 (2006 – USD 1 = Rs. 44.25)]. No representation is made that the Indian rupee amounts have been, could have been or could be converted into United States dollars at such a rate or any other rate.

2. Summary of Group's Significant Accounting Policies

The consolidated financial statements are prepared under the historical cost convention, on the accrual basis of accounting and in conformity with accounting principles generally accepted in India. These consolidated financial





statements have been prepared to meet the requirements of Clause 32 of the listing agreement with the stock exchanges. The significant accounting policies of the group are as follows:

(a) Fixed assets, depreciation/amortization and impairment

Fixed assets are stated at cost less accumulated depreciation/amortization and impairment loss if any. The Group capitalises all costs relating to the acquisition and installation of fixed assets.

The carrying amounts of fixed assets and intangible assets (including goodwill) are reviewed at each balance sheet date to assess whether they are recorded in excess of their recoverable amounts and where carrying values exceed the estimated recoverable amount, assets are written down to the recoverable amount. The recoverable amount is the greater of assets net selling price and value in use. In assessing value in use, the estimated future cash flows are discounted to their present values at the weighted average cost of capital.

Depreciation is provided, using the straight-line method, pro-rata to the period of use of assets, based on the estimated useful life of the assets.

Fixed assets whose aggregate cost is Rs. 5,000 or less are depreciated fully in the year of acquisition. Intangible assets except goodwill are amortised over a period of 3-15 years, which are based on their useful lives.

(b) Foreign currency translations

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of transaction.

Foreign currency monetary items are reported using closing rate. Non-monetary items, which are carried in terms of historical cost denominated in a foreign currency, are reported using the exchange rate at the date of transaction.

Exchange differences arising on the settlement of monetary items or on reporting Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise. Exchange differences arising in respect of fixed assets acquired from outside India on or before accounting period commencing before December 7, 2006 are capitalised as part of fixed assets.

Profit/loss on derivative financial instruments such as forward exchange contracts and interest rate swaps to hedge risks associated with foreign currency fluctuations and interest rates are considered as revenue items.

Premium or discount on forward exchange contracts arising at the inception of forward exchange contracts is amortized as expense or income over the life of the contract. Exchange differences on such contracts are recognized in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contract is recognized as income or as expense for the year.

(c) Investments

Long-term investments are stated at cost. Provision is made to recognise a diminution, other than temporary, in the value of investments. Investments that are readily realizable and intended to be held for not more than a year are classified as current investments. Current investments are carried at lower of cost and fair value determined on an individual investment basis.

(d) Inventories

All inventories are valued at moving weighted average price other than finished goods, which are valued on quarterly moving average price. Finished goods and Work in progress is computed based on respective moving weighted average of procured materials and appropriate share of labour and other manufacturing overheads.

Inventories are valued at cost or net realizable value, whichever is lower. Cost also includes all charges incurred for bringing the inventories to their present location and condition. Excise and customs duty accrued on production or import of goods, as applicable, is included in the valuation of inventories.

Inventories of samples and stores and spare parts are valued at cost.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and to make the sale.

(e) Employee benefits

Retirement benefits in the form of Provident Fund, Family Pension Fund, Super Annuation Schemes and non-contributory money purchase scheme, which are defined contribution schemes, are charged to the Profit & Loss Account of the year when the contributions to the respective funds accrue.

WUK operates defined contribution pension scheme. Till February 2004, WUK operated defined benefit pension scheme. The assets of schemes are held separately from those of the WUK in an independently administered fund.

Gratuity liability, which is a defined benefit scheme, and provision for leave encashment is accrued and provided for on the basis of an actuarial valuation made at the end of each financial year.





The Company maintains 401(k) retirement contribution plans that cover all regular employees on the payroll of Wockhardt USA, Inc (WUSA) & Morton Grove Pharmaceuticals, Inc. The Company makes a matching contribution on the first 6% and employee participation is allowable as per US Government laws. The assets of the plan are held separately from those of the Company in an independently administered fund.

Expenses on Voluntary Retirement Scheme incurred are charged off over a maximum period of 4 years. No such expenditure shall be carried forward to accounting periods commencing on or after 1st April, 2010.

(f) Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

Sale of Goods

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, which coincides with dispatch of goods to customers. Revenues are recorded at invoice value, net of excise duty, sales tax, value added tax (VAT), returns and trade discounts.

Sale of Services

Revenues from services are recognised on completion of such services.

Export Incentive

Benefit on account of entitlement to import duty free materials under the "Duty Entitlement Pass Book Schemes" is recognized in the year of export.

Royalties

Revenue is recognized on an accrual basis in accordance with the terms of the relevant agreement.

Interest

Revenue is recognized on a time proportion basis taking into account the amount outstanding and the rate applicable.

(g) Research and development (R & D)

Research costs are expensed as incurred. Development expenditure incurred on an individual project is carried forward when its future recoverability can reasonably be regarded as assured. Any expenditure carried forward is amortised over the period of expected future sales from the related project, not exceeding ten years.

The carrying value of development costs is reviewed for impairment annually when the asset is not yet in use, and otherwise when events or changes in circumstances indicate that the carrying value may not be recoverable.

(h) Income tax

Tax expense comprises of current, deferred and fringe benefit tax.

Current income tax and fringe benefit tax is measured at the amount expected to be paid to the tax authorities in accordance with the provisions of local Income Tax rules as applicable to the financial year. Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised.

Minimum Alternative Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. MAT credit becomes eligible to be recognized as an asset in accordance with the recommendations contained in the Guidance Note issued by the Institute of Chartered Accountants of India, the said asset is created by way of credit to the profit and loss account and shown as MAT credit entitlement. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT credit entitlement to the extent there is no longer convincing evidence to the effect that Company will pay normal income tax during the specified period.

Income tax charge is the simple aggregation of the tax charge appearing in the group companies.

(i) Leases

Operating leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the lease term are classified as operating lease. Operating lease payments are recognized as an expense in the Profit & Loss Account on a straight-line basis over the lease term.





Finance Lease

The assets are included in fixed assets and the capital elements of the leasing commitments are shown as obligations under finance leases and hire purchase contracts. The capital element is applied to reduce the outstanding obligations and the interest element is charged against profit in proportion to the reducing capital element outstanding. Assets held under finance leases are depreciated over the shorter of the lease terms and the useful lives of equivalent owned assets.

(j) Acquisitions and goodwill

On acquisition, the excess cost of acquisition over carrying value of assets acquired is treated as goodwill.

(k) Financing/Borrowing cost

Financing/Borrowing costs attributable to acquisition and/or construction of qualifying asset are capitalised as a part of the cost of such assets, up to the date such assets are ready for their intended use. Other financing/ borrowing costs are charged to Profit & Loss Account. Initial direct costs are recognised immediately as an expense.

Expenses incurred in connection with raising of funds are amortised over the tenure of the borrowing.

(I) Provisions

A provision is recognised when an enterprise has a present obligation as a result of past event, it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current best estimates.

(m) Earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period are adjusted for events of bonus issue to existing shareholders and share split.

For the purpose of calculating diluted earnings per share, the net profit attributable to equity shareholders and the weighted average number of shares outstanding are adjusted for the effects of all dilutive potential equity shares from the exercise of options on unissued share capital. The number of equity shares is the aggregate of the weighted average number of equity shares and the weighted average number of equity shares, which would be issued on the conversion of all the dilutive potential equity shares into equity shares. Options on unissued equity share capital are deemed to have been converted into equity shares.

(n) Government grants

Government grants in respect of capital expenditure are credited to a deferred income account and are released to the profit and loss account over the expected useful lives of the relevant assets. Grants of revenue nature are credited to income in the period to which they relate.

	As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]	As at 31.12.2006 Rs. in millions [Na	As at 31.12.2006 USD in millions [see note 1 (b) (d)] ote 31]
3. SHARE CAPITAL				
AUTHORISED				
250,000,000 (2006 – 250,000,000)			
Equity shares of Rs. 5 each	1,250.00	31.72	1,250.00	28.25
	1,250.00	31.72	1,250.00	28.25
ISSUED, SUBSCRIBED AND PAID UP				
109,435,903 (2006 – 109,435,903)			
Equity shares of Rs. 5 each fully paid	1			
up	547.18	13.88	547.18	12.37
	547.18	13.88	547.18	12.37

1. Of the above shares:

(a) 70,123,304 (2006 – 70,123,304) fully paid up equity shares of Rs. 5/- each were allotted pursuant to scheme of arrangement to demerge pharmaceuticals business of Carol Info Services Limited ('CISL') (formerly Wockhardt Life Science Limited).

(b) 2,400,000 (2006 – 2,400,000) fully paid up equity shares of Rs. 5/- each were allotted pursuant to amalgamation of Wockhardt Veterinary Limited ('WVL') with the Company.





Consolidated

- (c) 69,716,132 (2006 69,716,132) equity shares of Rs. 5/- fully paid up are held by Khorakiwala Holdings and Investments Private Limited, the holding company.
- 2. 439,200 (2006 439,200) fully paid equity shares of Rs. 5/- each were allotted pursuant to exercise of stock options.
- 3. 36,431,502 (2006 36,431,502) equity shares of Rs. 5/- each are allotted as Bonus shares out of Capital Redemption Reserve.

		As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]		As at 31.12.2006 USD in millions [see note 1 (b) (d)] te 31]
4.	RESERVES AND SURPLUS				
	Capital redemption reserve				
	Balance as per last accounts	265.34	6.73	265.57	6.00
	Utilised for issue of bonus shares	-	-	(0.23)	(0.01)
		265.34	6.73	265.34	5.99
	Securities premium account				
	Balance as per last accounts	134.14	3.40	117.07	2.65
	Additions: during the year	-	-	17.07	0.39
	<u> </u>	134.14	3.40	134.14	3.04
	Employee stock option outstanding	-	_	3.68	0.08
	Less: Deferredemployeecompensation expenses	_	-	_	_
	· · · · · · · · · · · · · · · · · · ·	_	_	3.68	0.08
	Capital reserve on consolidation				
	Balance as per last accounts	720.26	18.28	-	-
	Additions: during the year	-	-	720.26	16.28
		720.26	18.28	720.26	16.28
	Foreign currency translation reserve				
	Balance as per last accounts	72.21	1.83	81.28	1.84
	Deductions: during the year	(341.33)	(8.66)	(9.07)	(0.20)
		(269.12)	(6.83)	72.21	1.64
	General reserve				
	Balance as per last accounts	7,956.53	201.89	6,465.76	146.13
	Less: Adjustment for employee				
	benefit provision	-	-	(9.23)	(0.21)
	Transfer from profit and loss account	500.00	12.69	1,500.00	33.90
	Profit and loss account	8,456.53 2,881.28	<u>214.58</u> 73.11	7,956.53 963.53	<u> </u>
		12,188.43	309.27	10,115.70	228.62
5.	SECURED LOANS			10,112.10	223.02
	(A) Term loans				
	(i) From financial institutions	-	_	164.01	3.71
	(ii) From banks:	22,526.34	571.59	14,326.68	323.78
	(B) Working Capital Loans from Banks	913.84	23.19	260.05	5.88
		23,440.18	594.78	14,750.74	333.37

(A) Term Loans are secured as under:

(a) Foreign currency denominated loan (External Commercial Borrowings) are secured by mortgage and hypothecation of movable and immovable assets at Aurangabad, Ankleshwar, Daman, Biotech-Waluj, Cephal-Waluj (Plant & Machinery) and Research Centre, Aurangabad. The loans are repayable in July 2008, September 2008 and March 2009.

(b) Rupee denominated loans from banks includes an amount of Rs. 7.76 million (2006 – Rs. 19.08 millions) for purchase of vehicles and are secured by hypothecation of vehicles purchased under the agreement.





- (c) Loan amounting to Rs. 592.13 million (2006 Rs. 868.83 million) is secured against the fixed assets and working capital of Wockhardt UK Holdings Limited.
- (B) Working capital loans from banks are secured by hypothecation of inventories and debtors and specific charge on all tangible movable assets excluding plant and machinery tools, equipments, accessories, etc.

		As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]	As at 31.12.2006 Rs. in millions	As at 31.12.2006 USD in millions [see note 1 (b) (d)]
				[No	ote 31]
б.	UNSECURED LOANS				
	Long term				
	(A) Sales tax deferral loan	52.29	1.33	52.29	1.18
	 (B) Zero coupon foreign currency convertible bonds 	4,275.99	108.50	4,801.13	108.51
	(C) Short term Loans	1,231.28	31.24	98.58	2.23
		5,559.56	141.07	4,952.00	111.92

(A) 108,500 (2006 – 108,500) zero coupon foreign currency convertible bonds of USD 1,000 each are:

(a) Convertible by the holders at any time on or after 24 November, 2004 but prior to close of business on 25 September, 2009. Each bond will be converted into 94.265 fully paid up equity share with par value of Rs. 5 per share at a fixed price of Rs. 486.075 per share.

- (b) Redeemable in whole but not in part, at the option of the Company at any time on or after 25 October 2007 but not less than seven business days prior to maturity date i.e. 25 October, 2009 as per the terms and conditions of the bonds mentioned in the offering circular.
- (c) Redeemable on maturity date at 129.58 percent of its principal amount, if not redeembed or converted earlier.

		As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]		As at 31.12.2006 USD in millions [see note 1 (b) (d)] Note 31]
7.	DEFERRED TAX LIABILITY (Net)				
	Deferred tax liabilities				
	Difference between depreciation on block of assets (including CWIP)	1,385.28	35.15	1,101.14	24.89
	Total (A)	1,385.28	35.15	1,101.14	24.89
	Deferred tax assets				
	Provision for gratuity	32.16	0.82	31.71	0.72
	Provision for leave encashment	25.75	0.65	21.37	0.49
	Deferred expenses	139.56	3.54	(10.05)	(0.23)
	Tax Losses in Subsidiaries	124.80	3.17	-	_
	Provision for bonus	1.83	0.05	1.42	0.03
	Provision for doubtful debts	140.23	3.56	135.63	3.07
	Total (B)	464.33	11.79	180.08	4.08
	Net Deferred tax liability (A-B)	920.95	23.36	921.06	20.81
	Net deferred tax liability as of the year end	920.95	23.36	921.06	20.81





8 Fixed Assets

			Gross Block					Depreciation				Net B	lock	
PARTICULARS	As At	Additions	Deductions &	Exc.	As At	As At	Additions	Deductions &	Exc.	As At	As at 31.1	2.2007	As at 31.	12.2006
	01.01.2007		Transfers	Gain/	31.12.2007	01.01.2007		Transfers	Gain/	31.12.2007	Rs. In	USD in	Rs. In	USD in
				(Loss)					(Loss)		Millions	Millions	Millions	Millions
												See Note		See Note 1(b)(d)
Intangibles												1(b)(d)		1 (D)(U)
Goodwill on														1
Consolidation	5,626,06	10,179.22		-	15,805,28	6.72	-	-	(6.72)	-	15.805.28	401.05	5.619.34	126.99
Licenses & Dossiers	757.37	564.72	1.70	4.56	1,324.95	578.08	563.10	1.70	11.33	1,150.81	174.14	4.42	179.29	4.05
Trade Marks	1,221.00	156.53	69.07	(20.65)	1,287.81	357.41	129.37	69.97	(2.02)	414.79	873.02	22.15	863.59	19.52
Software	159.67	93.30	(3.17)	(6.12)	250.02	21.25	78.56	(6.87)	(3.71)	102.97	147.05	3.73	138.42	3.13
Total Intangibles A	7,764.10	10,993.77	67.60	(22.21)	18,668.06	963.46	771.03	64.80	(1.12)	1,668.57	16,999.49	431.35	6,800.64	153.69
Tangibles														
Freehold land	403.68	56.61	(2.45)	(32.03)	430.71	296.38	0.64	-	(26.93)	270.09	160.62	4.08	107.30	2.43
Leasehold land	83.41	178.10		0.88	262.39	4.76	4.40	-	(0.09)	9.07	253.32	6.43	78.65	1.78
Buildings	1,232.44	975.44	2.45	0.82	2,206.25	192.62	712.03	-	10.37	915.02	1,291.23	32.76	1,039.82	23.50
Electrical Fittings	1.11	-	-	-	1.11	0.33	0.05	-	-	0.38	0.73	0.02	0.78	0.02
Plant and Machinery	7,518.54	2,116.13	12.56	(164.90)	9,457.21	2,210.74	1,534.41	(38.04)	(78.61)	3,704.58	5,752.63	145.97	5,307.80	119.96
Furniture and fittings	202.78	93.98	-	(6.24)	290.52	77.38	47.45	-	(5.19)	119.64	170.88	4.34	125.40	2.83
Office Equipments	923.07	810.62	517.87	(9.06)	1,206.76	530.05	672.59	513.87	(2.61)	686.16	520.60	13.21	393.02	8.88
Information Technology														1
Equipments	296.57	133.41	0.03	(9.59)	420.36	214.10	75.47	0.03	(8.92)	280.62	139.74	3.55	82.47	1.86
Vehicles	100.62	2.10	30.40	(0.47)	71.85	54.69	13.79	20.74	(0.32)	47.42	24.43	0.62	45.93	1.04
Assets on Finance Lease	4.98	1.053.38	_	22.27	1.080.63	4.98	877.66	_	18.56	901.20	179.43	4.54		1
Total Tangibles B	10.767.20	5.419.77	560.86	(198.32)	15,427.79	3.586.03	3.938.49	496.60	(93.74)	6.934.18	8,493.61	4.54 215.52	7,181.17	162.30
Capital Work-	10,707.20	5,419.77	500.80	(190.52)	15,427.79	3,380.03	3,930.49	490.00	(95.74)	0,934.18	0,493.01	215.52	7,101.17	102.50
in-Progress :C:	[[1
(Inclusive of Capital	[[1
Advances)					5,219.59						5,219.59	132.44	3,085.91	69.74
Total A+B+C	18,531.30	16,413.54	628.46	(220.53)	39,315.44	4,549.49	4,709.52	561.40	(94.86)	8,602.75	30,712.69	779.31	17,067.72	385.73

 Total
 A+B+C
 18,531.30
 16,413.54
 628.46
 (220,53)
 39,315.44
 4,549.99
 4,709.52
 561.40
 (94.86)
 8,602.75
 30,712.69
 779.51
 17,067.72
 385.73

 The net block of tangible fixed assets includes an amount of Rs. 38.25
 million (206 - Rs. 60.10
 million) in respect of assets held under fixe Purchase contracts and Rs. 179.45
 million (206 - Rs. 10,91.22
 million).
 mespect of assets includes an amount of Rs. 38.25
 million (206 - Rs. 10,91.22
 million).
 mespect of assets held under fixe Purchase contracts and Rs. 179.45
 million (206 - Rs. 10,91.22
 million).
 mespect of assets includes expenditure that has been contracted but not provided for Rs. 835.25
 million (206 - Rs. 10,91.22
 million).
 million (206 - Rs. 590.15
 million).
 million.
 mespect of assets held under fixe expenses include Haerial Consumption Rs. 80.10
 million (Previous Year - Rs. 590.15
 million).
 million (Previous Year - Rs. 590.15
 million).
 million (Previous Year - Rs. 590.15
 million).
 million (Previous Year - Rs. 590.20
 million (Previous Year - Rs. 10.66
 million).
 million (Previous Year - Rs. 10.26
 million).
 million (Previous Year - Rs. 14.57
 million (Previous Year - Rs. 14.57
 million (Previous Year - Rs. 14.57
 million (Previous

inereon of NS. 3,324.06 million (2006 – NS. 617.04 millions) respectively.	As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]	As at 31.12.2006 Rs. in millions [No	As at 31.12.2006 USD in millions [see note 1 (b) (d)] ote 31]
9. INVESTMENTS				
LONG TERM INVESTMENTS (at Cost) Other than trade (Unquoted)				
305,982 (2006 – 305,982)				
shares of Bharuch Eco-Aqua				
Infrastructure Ltd of Rs. 10 each fully paid	3.05	0.08	3.05	0.07
6,300 (2006 – 6,300) shares	2.02	0.00	5.05	0.01
of Bharuch Environmental				
Infrastructure Ltd of Rs. 10 each	0.06		0.06	
fully paid 250 (2006 – 250) Shares of	0.00	-	0.00	-
Kanishka Housing Development Co.				
Pvt. Ltd. of Rs. 100 each fully paid	0.03	-	0.03	-
1,000 Shares of Saraswat Co-				
Op Bank Ltd. of Rs. 10 each fully paid up	0.01	_	_	_
Investment in Associates	0.01			
19,215,000 Equity shares of				
Swiss Bio Sciences AG (Refer note 27)	706.29	17.92		
	708.29	17.92	- 3.14	0.07
Units of Mutual Funds Purchased & Sold d				
10. INVENTORIES	5 /	Ύ,		/
Raw materials	2,340.47	59.39	1,453.76	32.86
Packing materials	154.12	3.91	173.75	3.93
Work-in-progess	763.76	19.38	534.32	12.08
Finished goods	4,297.94	109.06	2,010.72	45.44
Samples Stores and spare parts	30.33 131.13	0.77 3.33	30.73 96.68	0.69 2.19
	7,717.75	195.84	4,299.96	97.19





	As at 31.12.2007 Rs. in millions	As at 31.12.2007 USD in millions [see note 1 (b) (d)]		As at 31.12.2006 USD in millions [see note 1 (b) (d)] te 31]
11. SUNDRY DEBTORS Sundry debtors considered good Sundry debtors considered doubtful	6,700.65 473.13	170.02 12.01	4,615.65 480.99	104.34 10.87
Less: Provision for doubtful debts	7,173.78 (473.13)	182.03 (12.01)	5,096.64 (480.99)	115.21 (10.87)
Sundry Debtors, net of provisions/ charge back	6,700.65	170.02	4,615.65	104.34
12. CASH AND BANK BALANCES Cash on hand Balances with Scheduled banks	1.67	0.04	1.93	0.04
 on current accounts on margin accounts on deposit accounts [Includes unutilised amounts of FCCB 	590.93 23.92	14.99 0.61	472.53 24.53	10.68 0.55
Rs. 382.28 million (2006 – Rs. 4,214.78 million)]	3,185.26	80.82	9,232.79	208.66
13. LOANS AND ADVANCES	3,801.78	96.46	9,731.78	219.93
(Unsecured, considered good) Loans to employees Loans to companies Advances recoverable in cash or in	13.55 0.31	0.34 0.01	16.40 0.10	0.37
kind or for value to be received Accrued income Balance with customs and excise	766.11 8.88	19.44 0.23	548.08 33.66	12.39 0.76
authorities Loans to others Minimum alternate tax (MAT) credit	186.73 0.30	4.74 0.01	128.01 0.15	2.89 -
entitlement Advance taxes (including tax deducted at source) – net of	199.16	5.05	199.16	4.50
provisions for tax* Other deposits	179.83 533.71	4.56 13.54	79.52 371.65	1.80 8.40
* Advance Taxes are after netting off prov	1,888.58	47.92 of Rs. 235 50 Millions (1,376.73 2006 - R5, 47,26	5 Millions) Tax assets

Advance Taxes are after netting off provisions for taxes of Rs. 235.50 Millions (2006 – Rs. 47.26 Millions). Tax assets and liabilities are in accordance with respective countries Tax Legislations.


14. CURRENT LIABILITIES AND PROVISIONS CURRENT LIABILITIES Sundry creditors Lease finance Security deposits Investor education and protection fund shall be credited as & when due by the following amounts:	4,506.08 99.45 164.43	114.34 2.52 4.17	2,798.58 60.02 153.92	63.25 1.36 3.48
, Unclaimed dividends	15.15	0.38	9.04	0.20
Interest accrued but not due	140.21	3.56	21.75	0.49
Other liabilities	3,375.85	85.67	1,932.13	43.65
	8,301.17	210.64	4,975.44	112.43
PROVISIONS				
Interim dividend on equity shares	-	-	547.18	12.38
payable				
Tax on interim dividend payable	-	-	76.74	1.74
Proposed dividend	273.59	6.94	-	-
Tax on proposed dividend	46.50	1.18	-	-
Provision for retirement benefits	178.33	4.53	163.94	3.71
Other provision	75.00	1.90	45.00	1.02
	573.42	14.55	832.86	18.85
	8,874.59	225.19	5,808.30	131.28





		For the year ended 31.12.2007 Rs. in millions	For the year ended 31.12.2007 USD in millions [see note 1 (b) (d)]	For the year ended 31.12.2006 Rs. in millions [N	For the year ended 31.12.2006 USD in millions [see note 1 (b) (d)] ote 31]
15.	OTHER INCOMES				
	Dividends received on investments	0.08	-	0.73	0.02
	Profit/(Loss) on sale of assets Miscellaneous income	(7.57) 117.93	(0.19) 2.99	0.67 188.39	0.02 4.26
		110.44	2.80	189.79	4.30
16.	Material Consumed and Purchase of Goods				
	Consumption of raw and packing materials	7,373.89	187.11	5,085.45	114.93
	Purchase of finished goods	3,985.05	101.11	2,205.87	49.85
		11,358.94	288.22	7,291.32	164.78
17.	(INCREASE)/DECREASE IN INVENTORIES Inventories as at December 31, 2006				
	Finished goods	2,010.72	51.02	1,547.13	34.97
	Samples	30.73	0.78	24.63	0.56
	Work-in-progress Less: Excise duty on opening stock	534.33	13.56 (0.82)	180.25 (56.58)	4.07 (1.28)
	Less: Excise duty on opening stock	(32.21) 2,543.57	64.54	1,695.43	38.32
	Stock acquired on acquisition of	2,242.27	04.24	1,090.40	20.22
	Subsidiary Companies Finished goods	788.07	20.00	235.28	5.32
	Work-in-progress	306.85	7.79	0.03	
		1,094.92	27.79	235.31	5.32
	Inventories as at December 31, 2007				
	Finished goods	(4,297.94)	(109.06)	(2,010.72)	(45.44)
	Samples	(30.33)	(0.77)	(30.73)	(0.69)
	Work-in-progress	(763.76) 22.12	(19.38) 0.56	(534.33) 32.21	(12.08)
	Less: Excise duty on closing stock	(5,069.91)	(128.65)	(2,543.57)	(57.48)
		(1,431.42)	(36.32)	(612.83)	(13.84)
18	OPERATING AND OTHER EXPENSES	(1,401.40)	(30.32)	(012.05)	(15.01)
10.	Employee costs	4,678.69	118.72	2,691.98	60.84
	Travelling expenses	493.33	12.52	417.07	9.43
	Freight and forwarding	530.33	13.46	363.37	8.21
	Selling and distribution	707.16	17.94	524.34	11.84
	Commission on sales	220.30	5.59	179.02	4.05
	Power and fuel	476.60	12.09	439.54	9.93
	Rent, Rates and taxes	174.58	4.43	160.24	3.62
	Repairs and maintenance:				
	Machinery	169.50	4.30	113.01	2.55
	Buildings	23.51	0.60	17.99	0.41
	Others	123.55		119.90	2.71
	Stores and spare parts consumed	307.41	7.80	316.30	7.15
	Insurance	152.08	3.86	116.95	2.64
	Bad debts	51.18		8.84	0.20
	Miscellaneous expenses	2,105.63	53.43	1,140.70	25.78
19.	FINANCIAL EXPENSES (Net)	10,213.85	259.17	6,609.25	149.36
	Interest paid On term Loans	1,321.17	33.52	224.02	5.06
	Others Loans	316.96	8.04	185.33	4.19
		1,638.13	41.56	409.35	9.25
	Add: Exchange (gain)/loss on borrowings	(314.27)	(7.97)	(98.53)	(2.23)
	Less: Interest received	(349.57)	(8.87)	(284.43)	(6.43)
		974.29	24.72	26.39	0.59





		For the year ended 31.12.2007 Rs. in millions	For the year ended 31.12.2007 USD in millions [see note 1 (b) (d)]	-	For the year ended 31.12.2006 USD in millions see note 1 (b) (d)] te 31]
20. (a)	Annual commitments under non-cancellable operating				
	leases are:				
	Less than 1 year	25.78	0.65	21.38	0.48
	More than 1 year but less than 5 years	69.75	1.77	59.09	1.34
	More than 5 years	75.13	1.91	22.92	0.52
	· · · · · · · · · · · · · · · · · · ·	170.66	4.33	103.39	2.34
(b)	Annual commitments under finance leases are:				
	In 1 year or less	79.85	2.03	50.69	1.15
	More than 1 year but less than 5 years	63.63	1.61	44.80	1.01
	More than 5 years	8.76	0.22	-	-
	,	152.24	3.86	95.49	2.16
	Less: Finance charge	2.30	0.06	6.23	0.14
	Present value of minimum lease				
	payments	149.94	3.80	89.26	2.02
	Penditure on Research and Velopment				
Cap	bital	1,011.09	25.66	767.01	17.33
Rev	venue	504.59	12.80	610.41	13.80
		1,515.68	38.46	1377.42	31.13

22. EARNINGS PER SHARE

The calculations of earnings per share (basic and diluted) are based on the earnings and number of shares are computed as below:

Reconciliation of earnings	2007 Rs. in millions	2007 USD in millions	2006 Rs. in millions	2006 USD in millions
Profit after tax for the financial year	3,858.14	97.90	2,412.50	54.54
Net profit attributable to equity shareholders	3,858.14	97.90	2,412.50	54.54
Reconciliation of weighted average number of shares	Shares		Shares	
For basic earnings per share	109,435,903		109,419,237	
Add: Deemed exercise of options on unissued equity share capital	-		22,161	
For diluted earnings per share	109,435,903		109,441,398	
Earnings per share (nominal value Rs. 5 each)				
Basic	35.25	0.89	22.05	0.50
Diluted	35.25	0.89	22.04	0.50

23. SEGMENT INFORMATION

(i) Information about Primary Segments

The company is primarily engaged in pharmaceutical business which is considered as the only reportable business segment as per Accounting Standard - AS 17 'Segment Reporting' issued by the Institute of Chartered Accountants of India.

(ii) Information about Secondary Segments

Sales by market - The following is the distribution of the Company's sale by geographical market regardless of where the goods were produced:







Geographical segment	2007 Rs. in millions	2007 USD in millions	2006 Rs. in millions	2006 USD in millions
India	7,811.82	198.22	6,764.71	152.88
USA / Western Europe	16,813.47	426.63	8,808.31	199.07
Rest of the World	1,906.25	48.37	1,717.37	38.81
Total	26,531.54	673.22	17,290.39	390.76

Assets and additions to fixed assets by geographical area – The following table shows the carrying amount of segment assets and liabilities to fixed assets by geographical area in which the assets are located:

	India	India	Others	Others
	Rs. in millions	USD in millions	Rs. in millions	USD in millions
Carrying amount of segment assets	16,310.96	413.88	35,219.92	893.68
	(16,404.38)	(370.74)	(20,737.86)	(468.68)
Additions to tangible and intangible assets	736.45	18.69	11,752.40	298.21
	(2,266.40)	(51.22)	(6,749.87)	(152.55)

(iii) Notes:

Geographical segments: Secondary segmental reporting is performed on the basis of the geographical location of customers. The management views the Indian market and export markets as distinct geographical segments.

Segment assets: Segment assets include all operating assets used by a segment and consist principally of debtors, inventories, advances and fixed assets, net of allowances. Assets at the corporate level are not allocable to segments on a reasonable basis and thus the same have not been allocated.

Figures in brackets represent prior year comparatives

24. RELATED PARTY DISCLOSURES

(a) Parties where control exists

Holding company

Khorakiwala Holdings and Investments Private Limited

(b) Related party relationships where transactions have taken place during the period

Fellow Subsidiary

Carol Info Services Limited

Associates Enterprises

Khorakiwala Foundation

Key management personnel

H F Khorakiwala, Chairman and Managing Director Rajiv B Gandhi, Whole Time Director

(c) Transactions with related parties during the period

	R	2007 s. in millions	2007 USD in millions	2006 Rs. in millions	2006 USD in millions
Holding compa	any				
Dividend Paid		958.60	24.32	348.58	7.88
Fellow Subsidi enterprises	ary/Associate				
Limited –Rs. 2 Info Services L	paid [(2006 – Merind 52.65 million), Carol imited Rs. 75.76 - Rs. 69.20 million)]	75.76	1.92	321.85	7.27
Limited Rs. 51	ol Info Services .93 million (2006 – on), (2006 – Merind 42 million)1	51.93	1.32	50.01	1 13



														(
														(
۲	•	•	۲	•	۲	•		•			•	•	۲	(
	•													
۲	•	•	•	•	•	•	•	•	•	•	•	•	•	(

		2007 Rs. in millions	2007 USD in millions	2006 Rs. in millions	2006 USD in millions
	Expenses recovered/(paid) [Carol Info Services Limited Rs. 15.60 million (2006 – Rs. 10.80 million), Khorakiwala Foundation Rs. 0.81				
	million (2006 – Rs. 2.59 million)]	16.41	0.42	13.39	0.30
	Donation given [Khorakiwala				
	Foundations Rs. 2.70 million (2006 – Rs. Nil)]	2.70	0.07		
	Security deposit given [(2006 – Merind Limited – Rs. 280 million), Carol Info Services Limited Rs. 250 million (2006 – Rs. 250	2.70	0.07		_
	million)] Security deposit recovered [(2006 – Merind Limited – Rs. 280 million),	250.00	6.34	530.00	11.98
	Carol Info Services Limited Rs. 250 million (2006 – Rs. 250 million)]	250.00	6.34	530.00	11.98
	Key management personnel				
	Remuneration to Directors:				
	Salary	16.87	0.43	11.50	0.26
	Commission	70.96	1.80	71.18	1.61
	Contribution to Providend Fund	1.32	0.03	1.22	0.03
	Other Perquisites	0.78	0.02	1.43	0.03
		89.93	2.28	85.33	1.93
(d)	Related party balances				
	Payable to associate enterprises				
	[(2006 – Merind Limited – Rs. 21.49 million), Carol Info Services Limited Rs. 15.15 million (2006 – Rs. 14.77 million)]	(15.15)	(0.38)	(36.26)	(0.82)
	Payable to Key management personnel – Chairman and Managing Director	(70.96)	(1.80)	(71.18)	(1.61)

25. Turnover includes exchange rate gain, including gain on hedging activity, of Rs. 843.96 million (2006 – Rs. 829.50 million).

26. Provision for Sales Return, date expiry and chargebacks - Opening Balance Rs. 116.67 million (2006 – 26.11 million), Additions during the year Rs. 140.65 million (2006 – Rs.156.30 million), utilised during the year Rs. 139.13 million (2006 – Rs. 64.16 million), Closing Balance Rs. 111.56 million (2006 – Rs. 116.67) [(Net of exchange Rs. 6.62 million (2006 – Rs. 1.58 million)].

27. INVESTMENT IN ASSOCIATE COMPANIES

Investment in associate include goodwill of Rs. 543.21 Millions (2006 – Nil). The holding interest of Wockhardt group in Swiss Bio Sciences AG is 45 % (2006 – Nil)

28 CONTINGENT LIABILITIES NOT PROVIDED FOR:

- (a) Demands by Central Excise authorities in respect of Classification/Valuation/Cenvat Credit related disputes; stay orders have been obtained by the Company in case of demands which have been confirmed – Rs. 63.01 million (2006 – Rs. 66.67 million).
- (b) Demand by Income tax authorities Rs. 535.35 million (2006 Rs. 408.53 million) disputed by the Company.
- (c) A Government grant of Rs. 44.46 million (2006 Rs. 37.80 Millon) received by Pinewood Limited, which pertains to periods prior to acquisition, is repayable only if certain conditions are not fulfilled.
- (d) 108,500 (2006 108,500) Zero coupon foreign currency convertible bonds of USD 1,000 each are:
 - Convertible by the holders at any time on or after November 24, 2004 but prior to close of business on September 25, 2009. Each bond will be converted into 94.265 fully paid up equity share with par value of Rs. 5 per share at a fixed price of Rs. 486.075 per share.



- (ii) Redeemable, in whole but not in part, at the option of the Company at any time on or after October 25, 2007 but not less than seven business days prior to maturity date i.e October 25, 2009 subject to the fulfillment of certain terms and obtaining requisite approvals.
- (iii) Redeemable on maturity date at 129.57 percent of its principal amount, if not redeemed or converted earlier.

The Bonds are considered as monetary liability. The bonds are redeemable only if there is no conversion of the bonds earlier. Hence the payment of premium on redemption is contingent in nature, the outcome of which is dependent on uncertain future events. Hence no provision is considered necessary nor has been made in the accounts in respect of such premium amounting to a maximum of Rs. 775.98 million (2006 - Rs. 581.74 million).

(e) Contingent liability in respect of VAT for Wockhardt UK Holding Limited and its subsidiaries amounts Rs. Nil (2006 – Rs. 169.06 million).

29. EMPLOYEE BENEFIT

(A) Defined Benefit Plans:

	200	7	2006		
	Gratuity (Non-funded)	Leave Encashment (Non-funded)	Gratuity (Non-funded)	Leave Encashment (Non-funded)	
 Expenses recognised during the year ended December 31, 2007 				· · · ·	
1. Current Service Cost	15.07	7.49	7.79	6.60	
2. Interest cost	7.81	4.68	4.76	2.59	
3. Actuarial Losses/(Gains)	(12.14)	17.15	4.90	14.90	
Total Expenses	10.74	29.32	17.45	24.09	
II. Net Asset/(Liability) recognised in the Balance Sheet as at December 31, 2007					
 Present value of defined benefit obligation 	94.62	75.75	94.20	63.50	
2. Net Asset/(Liability)	(94.62)	(75.75)	(94.20)	(63.50)	
III. Reconciliation of Net Asset/(Liability) recognised in the Balance Sheet during the period ended December 31, 2007					
 Net Asset/(Liability) at the beginning of the year 	(94.20)	(63.50)	(84.94)	(48.67)	
2. Expense as per l above	10.74	29.32	17.45	24.09	
3. Employer contributions	10.32	17.07	8.19	9.26	
Net asset/(liability) at the end of the year	(94.62)	(75.75)	(94.20)	(63.50)	
Experience adjustment	5.76	N.A.	4.90	N.A.	
IV. Actuarial Assumptions:	As at 31.1	.2.2007	As at 31	.12.2006	
1. Discount rate	8.00	%	7.5	50%	
2. Mortality	LIC (1994-96	5) Ultimate	LIC (1994-9	96) Ultimate	

Note: (a) Amounts recognized as an expense and included in the Schedule 18:

"Retirement benefits" are gratuity Rs. 8.68 million (Previous Year – Rs. 17.46 million), Leave Encashment Rs. 29.67 million (Previous Year – Rs. 31.34 million).

(b) Actuarial valuation is worked out considering attrition rate and estimates of future salary increase taking into account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(c) In the previous year, the Company had gone for earlier adoption of Accounting Standard 15 (Revised) which is mandatory from accounting periods starting from December 7, 2006. Accordingly, the Company had provided for gratuity and leave encashment based on actuarial valuation done as per Projected Unit Credit Method. Further, in accordance with the transitional provision in the revised Accounting Standard, Rs. Nil [Previous Year – Rs. 9.23 million (net of tax liability Rs. 4.68 million)] has been adjusted to the General Reserve.





(B) Defined contribution plan:

Amount recognised as an expense and included in the Schedule 18 - "Contribution to provident and other funds" of Profit and Loss Account Rs. 505.45 million (Previous Year – Rs. 160.52 million).

30. DISCLOSURE REGARDING DERIVATIVE INSTRUMENTS AND UNHEDGED FOREIGN CURRENCY EXPOSURE

- (a) The Company enters into forward exchange contracts being derivative instruments, which are not intended for trading, or speculative purposes, but for hedge purposes, to establish the amount of reporting currency required or available at the settlement date of certain payables and receivables.
- (b) Outstanding currency swaps (other than forward exchange contracts stated above) to hedge against fluctuations in changes in exchange rate and interest rate changes:

		200)7	2006			
	No. of contracts	2		2			
		USD in millions	Rs. in millions	JPY in millions	Rs. in millions		
	National principal	100.00	3,941.00	4,158.83	1,548.75		
<i>~</i> ~	The second						

(c) The year end foreign currency exposures that have not ben hedged by a derivative instrument or otherwise are given below:

		2007			2006	
Particulars	Currency	Amt. in Foreign	Rs. in	Currency	Amt. in Foreign	Rs. in
		Currency (in millions)	millions		Currency (in millions)	millions
Loan Availed	USD	50.00	1,970.50	USD	50.26	2,223.82
				GBP	1.03	89.86
Interest Payable	USD	0.72	28.28	USD	0.48	21.27
Sundry Debtors	ACU	0.16	6.42	ACU	0.03	1.12
	AUD	0.01	0.48	AUD	0.01	0.48
	CHF	0.04	1.54	CHF	-	-
	EUR	5.45	315.66	EUR	0.57	33.48
	GBP	3.41	268.83	GBP	4.26	369.87
	USD	59.31	2,337.28	USD	33.08	1,463.87
Loans and Advances	EUR	3.02	175.03	EUR	3.02	175.94
	USD	21.83	860.16	USD	1.82	80.71
	CHF	0.04	1.29	CHF	-	-
	GBP	-	-	GBP	5.22	452.88
Sundry Creditors	ACU	0.001	0.05	ACU	-	-
	AUD	0.0002	0.01	AUD	0.004	0.15
	CAD	0.01	0.22	CAD	-	-
	CHF	0.08	2.68	CHF	0.06	2.20
	EUR	1.10	63.62	EUR	0.21	12.51
	GBP	0.46	36.09	GBP	0.97	84.00
	JPY	15.83	5.56	JPY	48.48	18.05
	SEK	0.23	1.44	SEK	-	_
	USD	8.48	334.04	USD	8.02	355.00
5	ZAR	0.001	-	ZAR	-	-
Foreign Currency	1150	100 50	4 775 00		100 50	4 001 17
Convertible Bonds	USD	108.50	4,275.99	USD	108.50	4,801.13
Time Deposit	USD	9.70	382.28	USD	95.25	4,214.78

31. PREVIOUS YEAR COMPARATIVES

Previous year's figures have been re-grouped where necessary to conform to this year's classification.

As per our report of even date

For S. R. Batliboi & Co. Chartered Accountants

per Vijay Bhatt *Partner* Membership No: 36647

Place : Mumbai Date : February 20, 2008

42

R. B. Gandhi Company Secretary For and on behalf of the Board of Directors

H. F. Khorakiwala Chairman and Managing Director

B. L. Maheshwari Shekhar Datta Aman Mehta Bharat Patel R. A. Shah Abid Hussain Directors